Biopsychosocial impact of prostate cancer and androgen-deprivation therapy

Authors

  • Dean A. Tripp Department of Psychology, Anesthesiology and Urology, Queen's University
  • Phylicia Verreault Department of Psychology, Queen's University
  • Steven Tong Department of Urology, Queen's University
  • Jason Izard Department of Urology, Queen's University
  • Angela Black Department of Urology, Queen's University
  • D. Robert Siemens Department of Urology, Queen's University

DOI:

https://doi.org/10.5489/cuaj.4499

Abstract

Introduction: Prostate cancer is the most non-cutaneous malignancy in men, and androgen-deprivation therapy (ADT) is a cornerstone of management in advanced disease. The aim of this study was to evaluate the association of ADT with changes in depression and mental and physical quality of life (QoL) within a prospective patient cohort design.

Methods: Patients were prospectively recruited and consented at a single academic health sciences centre in Ontario, Canada. Inclusion criteria included those men with adenocarcinoma of the prostate and either on watchful waiting or initiating ADT as palliation or as an adjuvant therapy for high-risk localized disease. All three cohorts were followed in routine care and completed psychosocial evaluations, including depression, social support, anxiety, and QoL measures.

Results: In comparison to the control cohort of patients with prostate cancer on watchful waiting, initiation of ADT over a two-year period of time was not associated with any changes in depression or mental QoL. Instead, all patients, regardless of treatment cohort, showed increased depression scores and reduced mental QoL scores over time; however, for patients receiving ADT, a significant reduction in physical QoL compared to patients who did not receive ADT was demonstrated.

Conclusions: ADT does not appear to significantly impact depressive symptoms and mental QoL over a two-year period; however, the depressive symptoms in this limited sample of men with prostate cancer was higher than expected and monitoring for these may be advisable for those who care for such patients.

Downloads

Download data is not yet available.

Downloads

Published

2017-10-12

How to Cite

Tripp, D. A., Verreault, P., Tong, S., Izard, J., Black, A., & Siemens, D. R. (2017). Biopsychosocial impact of prostate cancer and androgen-deprivation therapy. Canadian Urological Association Journal, 11(10), 338–43. https://doi.org/10.5489/cuaj.4499

Issue

Vol. 11 No. 10 (2017): CUAJ October

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.